EDAP is a global leader in therapeutic ultrasound. The company markets its Ablatherm for high-intensity, focused ultrasound (HIFU) treatment of localized prostate cancer. HIFU treatment of prostate cancer is shown to be a minimally invasive and effective treatment option with a low occurrence of side effects.
The company announced today that it received CE Mark (European regulatory approval) for Focal.One, its new and innovative robotic HIFU device dedicated to focal therapy of prostate cancer while preserving patient quality of life. Utilizing a focal therapy approach to target the cancer cells within the prostate gland is gaining wider acceptance in the global urological community.
EDAP’s Focal.One is the first device fully dedicated to the focal approach to prostate cancer therapy. It combines the three essential components to efficiently perform a focal treatment: state-of-the-art imaging to localize tumors with the use of MRI technology combined with real-time ultrasound, utmost precision of HIFU treatment focused on identified cancer areas only, and immediate feedback on treatment efficacy utilizing contrast-enhanced ultrasound imaging.
The CE Mark positions the company’s Focal.One device for full commercialization in Europe and in many other countries. EDAP’s unique and exclusive range of HIFU products offers perhaps the widest array of treatment options to patients with prostate cancer. For additional information about EDAP TMS and its entire product line, please visit www.edap-tms.com or www.hifu-planet.com.
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website
http://www.missionir.com/disclaimer.html
